Literature DB >> 12382649

Eosinophilia indicates the evolution to acute graft-versus-host disease.

Nadezda Basara, Michael G Kiehl, Axel A Fauser.   

Abstract

Entities:  

Mesh:

Year:  2002        PMID: 12382649     DOI: 10.1182/blood-2002-04-1118

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Elevated bone marrow eosinophil count is associated with high incidence of severe acute GvHD after allogeneic hematopoietic stem cell transplantation.

Authors:  Y Shimomura; M Hara; H Hashimoto; T Ishikawa
Journal:  Bone Marrow Transplant       Date:  2017-06-19       Impact factor: 5.483

2.  Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.

Authors:  Hiroki Hosoi; Shogo Murata; Toshiki Mushino; Akinori Nishikawa; Takashi Sonoki
Journal:  Ann Hematol       Date:  2020-08-21       Impact factor: 3.673

Review 3.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Thomas B Nutman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

4.  Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome.

Authors:  Fabian Beier; Klaus Arbter; Nicolai A Kittan; Reinhard Andreesen; Stefan W Krause; Ernst Holler; Gerhard C Hildebrandt
Journal:  Mol Clin Oncol       Date:  2013-09-25

5.  Eosinophils in the blood of hematopoietic stem cell transplanted patients are activated and have different molecular marker profiles in acute and chronic graft-versus-host disease.

Authors:  Julia Cromvik; Marianne Johnsson; Krista Vaht; Jan-Erik Johansson; Christine Wennerås
Journal:  Immun Inflamm Dis       Date:  2014-07-07

6.  Retrospective Study of Incidence and Prognostic Significance of Eosinophilia after Allogeneic Hematopoietic Stem Cell Transplantation: Influence of Corticosteroid Therapy.

Authors:  Wataru Yamamoto; Eriko Ogusa; Kenji Matsumoto; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.